Bevacizumab is used in:
**Core Concept**
Bevacizumab is a **monoclonal antibody** that targets **vascular endothelial growth factor (VEGF)**, a key mediator of **angiogenesis**. This mechanism is crucial in the treatment of various cancers. Bevacizumab's role in inhibiting tumor growth by blocking VEGF is a fundamental concept in oncology.
**Why the Correct Answer is Right**
Bevacizumab is used in the treatment of several types of cancer, including **colorectal**, **lung**, **breast**, and **glioblastoma**, among others. Its anti-angiogenic properties help in reducing the growth of new blood vessels that supply the tumor, thereby inhibiting tumor progression. This is achieved by binding to VEGF, preventing its interaction with **VEGF receptors** on the surface of endothelial cells.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because while bevacizumab is used in cancer treatment, the specific option provided is not applicable without the actual option text.
**Option B:** Similarly, without the actual text, we cannot specify why it's incorrect, but typically, bevacizumab's use is more targeted than what might be suggested by a broadly incorrect option.
**Option C:** Again, lacking the specific details of option C, we can say that bevacizumab's use is well-defined in oncology, making incorrect options stand out due to their inaccuracy regarding its application.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that bevacizumab's use can be associated with specific side effects due to its anti-angiogenic effects, such as **hypertension** and **proteinuria**. Monitoring for these side effects is crucial in patients receiving bevacizumab.
**Correct Answer:** Correct Answer: D. Colorectal cancer.